Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ASCEND Data Puts InterMune’s Pirfenidone On Top

Feb 26 2014

• By Sarah Karlin-Smith

Related Content

Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF

Mar 15 2010

Despite Positive Advisory Committee Vote, InterMune Gets Complete Response For Pirfenidone

May 04 2010

U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts

Apr 23 2013

After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

Mar 26 2012

Related Companies

InterMune, Inc.

Boehringer Ingelheim GmbH

Additional Topics

United States Europe Clinical Trials Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window